Startups
Innovation-driven drug and device company with a focus on minimally toxic therapies for cancer and chronic diseases. #cancertherapy #biotech
Overview
Location
United States, California, Anaheim
Total raised
$35M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 15, 2019 | EpicentRx raises $35M to fund late-phase lung cancer trial | EpicentRx has raised $35 million for late-phase development of RRx-001. The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. RRx-001 advanced into phase 3 on t... |
| Nov 15, 2019 | EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform | LA JOLLA, Calif.--(BUSINESS WIRE)--EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has raised a $35 million Serie... |
| Nov 15, 2019 | EpicentRx raises $35M to fund late-phase lung cancer trial W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | EpicentRx has raised $35 million for late-phase development of RRx-001. The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. Sponsored by Agilent Technologies ... |
| Nov 14, 2019 | EpicentRx has raised $35M of Series D financing to improve the delivery of cancer treatments with minimal toxicity. | |
| Nov 13, 2019 | EpicentRx Closes $35M in Series D Financing | EpicentRx, Inc., a La Jolla, Calif.-based clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, raised $35m in Series D funding. The backer was an undisclosed inv... |
Reviews 0
FAQ about EpicentRx, Inc.
How much funding has EpicentRx, Inc. raised?
EpicentRx, Inc. has raised $35M in total across 1 funding round.
What has the press written about EpicentRx, Inc.?
Parsers VC has collected 6 articles mentioning EpicentRx, Inc., among them “EpicentRx raises $35M to fund late-phase lung cancer trial” (Nov 15, 2019) and “EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform” (Nov 15, 2019).
Is EpicentRx, Inc. still active?
Yes, EpicentRx, Inc. is active; its latest activity on Parsers VC dates from Jan 6, 2021.